Evaluating the L-MIND and RE-MIND2 Trials in the Real-World Setting

Opinion
Video

Matthew Lunning, DO, FACP, evaluates the clinical trial data from the L-MIND and RE-MIND2 studies, discussing the impact of tafasitamab + lenalidomide on real-world outcomes.

Recent Videos
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Related Content
Data Shows Subcutaneous Rituximab Similar to IV in Non-Hodgkin Lymphoma

Data Shows Subcutaneous Rituximab Similar to IV in Non-Hodgkin Lymphoma

Ariana Pelosci
September 9th 2024
Article

Subcutaneous and intravenous forms of rituximab showed similar efficacy in patients with non-Hodgkin lymphoma.

Read More

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

Nichole Tucker
July 15th 2022
Podcast

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

Listen

Clinically Meaningful Efficacy Observed in R/R PTCL With Valemetostat

Clinically Meaningful Efficacy Observed in R/R PTCL With Valemetostat

Chris Ryan
September 9th 2024
Article

Valemetostat showed promise as a treatment option for patients with relapsed/refractory peripheral T-cell lymphoma.

Read More

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

Nichole Tucker
June 15th 2022
Podcast

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Listen

Improved Sensitivity Leads to Expanded MRD Use in Lymphoma

Improved Sensitivity Leads to Expanded MRD Use in Lymphoma

Jason M. Broderick
September 5th 2024
Article

Reid W. Merryman, MD, discussed the latest developments with minimal residual disease assays in the management of patients with lymphoma.

Read More

Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point

Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point

Jordyn Sava
August 16th 2024
Article

The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.

Read More